Related Experiment Video
Updated: Feb 25, 2026
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10
Iulia Andras1,2, Nicolae Crisan1,2, Stefan Vesa3
1Department of Urology, Iuliu Hatieganu University of Medicine & Pharmacy, Cluj-Napoca, Romania.
Aim:
To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy.
Patients & Methods:
Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed.
Results:
Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy.
Conclusion:
Metabolomic analysis can predict the outcome of the first systematic biopsy.
